$FEMY News

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

Femasys Doubles Number Of Enrolling Facilities To 12 In Its FemBloc FINALE Pivotal Study Across U.S.

Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

Femasys Files Prospectus Related To The Offer And Resale From Time To Time By The Selling Stockholders Of Up To An Aggregate Of 28,124,997 Shares Of Common Stock

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

Femasys Partners With UNC Health To Introduce Fertility Diagnostics, FemVue And SpermVue, Together With Femaseed Complete Within UNC Health OB/GYN Practice Locations

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential

Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

Femasys Q2 EPS $(1.08) Beats $(1.33) Estimate, Sales $756.716K Beat $730.667K Estimate

Maxim Group Maintains Buy on Femasys, Lowers Price Target to $10

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million